--- title: 'Industry Daily Summary: What Happened on November 2, 2026' headline: Alligator sells mitazalimab rights to Biossil for $750,000 upfront description: Fresenius and WuXi formed a biosimilar alliance. url: https://thebench.bio/news/industry/2026-11-02 topic: industry date: '2026-11-02' covers: - '2026-11-02' date_published: '2026-11-02T12:02:45Z' date_modified: '2026-11-02T12:02:45Z' tags: - Industry sources: 2 publisher: TheBench.Bio --- # Industry Daily Summary: What Happened on November 2, 2026 **Alligator sells mitazalimab rights to Biossil for $750,000 upfront** Fresenius and WuXi formed a biosimilar alliance. ## Today in brief Biossil will take over worldwide rights to Alligator Bioscience’s mitazalimab, paying $750,000 upfront plus potential milestones and royalties. [1] The transfer shifts future development costs to Biossil after Alligator halted independent development in July. [1] ## Also worth knowing - Fresenius and WuXi formed an alliance focused on biosimilars. [2] ## The day in numbers - **$750,000**: Upfront payment to Alligator for worldwide mitazalimab rights. [1] - **Up to $108 million**: Potential milestone payments under the mitazalimab deal, in addition to royalties. [1] ## Also published - [What is it Like to Go From Treating Patients Directly to Running a Company?](), Pharmaceutical Executive - [Breaking the silos: What effective scenario modeling looks like in 2026 and beyond](), BioPharma Dive - [Evolution Summit 2027 to Convene Senior Clinical Development Leaders in Westlake Village, California](), pharmaphorum - [Notable TechBio startups and companies operating in Thailand 🇹🇭](), MetaphysicalCells ## Sources 1. [Alligator sells cancer antibody for $750,000 upfront after abandoning development](), European Biotechnology, 2026-11-02 2. [Fresenius doubles down on biosimilars with big WuXi alliance](), pharmaphorum, 2026-11-02 --- TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing. [1]: [2]: